| Nov 9 |
M&A deals roundup: Blackstone, BCE, CrowdStrike, Danone and more
|
| Nov 7 |
Indivior jumps amid investor letter, takeover speculation (update)
|
| Nov 7 |
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior
|
| Oct 17 |
Two Seas Capital LP Increases Stake in Indivior PLC
|
| Oct 7 |
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
|
| Sep 25 |
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
|
| Sep 23 |
Top 3 Health Care Stocks That May Explode This Month
|
| Sep 6 |
Smith & Wesson Brands Reports Downbeat Results, Joins Planet Labs PBC, Broadcom And Other Big Stocks Moving Lower In Friday's Pre-Market Session
|
| Sep 5 |
French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior Will Not Exercise Option
|
| Sep 4 |
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
|
